Bimekizumab 3-Year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3 3b Trials. J of Skin 2024, 8 (1), s304. https://doi.org/10.25251/skin.8.supp.304.